Stockreport

eFFECTOR Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

eFFECTOR Therapeutics, Inc.  (EFTR) 
PDF •   Continuing to enroll patients in Phase 2b KICKSTART study of tomivosertib in combination with pembrolizumab, a U.S. Food and Drug Administration (FDA) approved PD-1 [Read more]